FORM 6-K

SECURITIES AND EXCHANGE COMMISSION

~~WASHINGTON~~Washington, D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of

the Securities Exchange Act of 1934

Dated December ~~August 8~~ 12, ~~2005~~2006

BIOMIRA INC.

(Translation of registrant’s name into English)

Edmonton Research Park

2011-94 Street, Edmonton, Alberta Canada T6N1H1

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ýx (for past years ~~ending~~through in calendar year 1996) Form 40-F ýx (commencing in calendar year 1997)

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes o No ýx

If “Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b):

~~TABLE~~EXPLANATORY ~~OF CONTENTS~~ NOTE

Item	Page
Quarterly Report of the Company mailed to Shareholders on or about August 5, 2005 (Note that only the cover page of the Report is attached because the balance of the Report is identical to the earnings press release filed with a Form 6-K on July 27, 2005, except only that the heading on the first page has been changed from “NEWS RELEASE FOR IMMEDIATE RELEASE” to “SECOND QUARTER REPORT” and opposite that heading on the left side the Company's address and website have been added on the right side, as follows "2011-94 Street, Edmonton, Alberta T6N 1H1 Web site: www.biomira.com)		3
Canadian Certification of the Company’s Chief Executive Officer of Interim Filings During the Transition Period (Form 52-109 FT2) filed on SEDAR on August 5, 2005		4
Canadian Certification of the Company’s Chief Financial Officer of Interim Filings During the Transition Period (Form 52-109 FT2) filed on SEDAR on August 5, 2005		5
Signature		6

On December 12, 2006, Biomira Inc. (i) issued a press release announcing an agreement with the U.S. Food and Drug Administration on a Special Protocol Assessment for the planned Phase III clinical trial of Stimuvax(R) for the treatment of non-small cell lung cancer and (ii) filed with the System for Electronic Document Analysis and Retrieval in Canada a Material Change Report related to the announcement. A copy of the press release is attached to this report as Exhibit 1 and a copy of the Material Change Report is attached to this report as Exhibit 2.

2EXHIBIT INDEX

Biomira Inc. 2011-94 Street Edmonton, AB T6N 1H1 June 2005 Second Quarter Report

Exhibit Number		Description of Document
1		Press Release dated December 12, 2006
2		Material Change Report dated December 12, 2006

Trading Information: NASDAQ National Market (symbol “BIOM”) The Toronto Stock Exchange (symbol “BRA”) For Information Contact: Edward Taylor Vice President Finance and Administration/Chief Financial Officer Jane Tulloch Director, Investor Relations & Compliance Officer E-Mail: ir@biomira.com Web: www.biomira.com

Biomira: The Cancer Vaccine PeopleÔ 1

Form 52-109FT2 - Certification of Interim Filings during Transition Period

I, T. Alexander McPherson, MD, PhD., President and CEO, certify that:
1.	I have reviewed the interim filings (as this term is defined in Multilateral Instrument 52-109 Certification of Disclosure in Issuers’ Annual and Interim Filings) of Biomira Inc. for the quarter ending June 30, 2005;
2.	Based on my knowledge, the interim filings do not contain any untrue statement of a material fact or omit to state a material fact required to be stated or that is necessary to make a statement not misleading in light of the circumstances under which it was made, with respect to the period covered by the interim filings; and
3.	Based on my knowledge, the interim financial statements together with the other financial information included in the interim filings fairly present in all material respects the financial condition, results of operations and cash flows of the issuer as of the date and for the periods presented in the interim filings.

August 5, 2005

T. Alexander McPherson

President and CEO

Form 52-109FT2 - Certification of Interim Filings during Transition Period

I, Edward A. Taylor, Vice President Finance and Administration and Chief Financial Officer, certify that:

1. I have reviewed the interim filings (as this term is defined in Multilateral Instrument 52-109 Certification of Disclosure in Issuers’ Annual and Interim Filings) of Biomira Inc. for the quarter ending June 30, 2005; 2. Based on my knowledge, the interim filings do not contain any untrue statement of a material fact or omit to state a material fact required to be stated or that is necessary to make a statement not misleading in light of the circumstances under which it was made, with respect to the period covered by the interim filings; and 3. Based on my knowledge, the interim financial statements together with the other financial information included in the interim filings fairly present in all material respects the financial condition, results of operations and cash flows of the issuer as of the date and for the periods presented in the interim filings.

August 5, 2005

Edward A. Taylor

Vice President, Finance & Administration

and Chief Financial Officer

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	BIOMIRA INC.
	(Registrant)
Date: August 8, 2005	By:	/s/ Edward A. Taylor
Date: December 12, 2006	By:	/s/ Edward A. Taylor
		Edward A. Taylor
		Edward A. Taylor Vice President, Finance & Administration and Chief Financial Officer
		Vice President, Finance & Administration
		and Chief Financial Officer

Filing Compare · BIOMIRA INC